SCHEMBL3493547

SCHEMBL3493547

Cc1c(C(=O)O)sc2nc(Oc3ccccc3)[nH]c(=O)c12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 6/20 0.52
POLB P06746 5/20 0.52
TSHR P16473 1/20 0.49
BCAT2 O15382 1/20 0.49
ALDH1A1 P00352 8/20 0.48
MAPT P10636 6/20 0.48
GAA P10253 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
KMT2A Q03164 6/20 0.48
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 5/20 0.47
HPGD P15428 2/20 0.47
APEX1 P27695 1/20 0.47
RECQL P46063 1/20 0.47
MCL1 Q07820 1/20 0.47
L3MBTL1 Q9Y468 3/20 0.46
LMNA P02545 1/20 0.45
RAB9A P51151 2/20 0.45
ALPL P05186 1/20 0.45
USP2 O75604 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4519694 0.88 KMT2A (0.64) POLBTSHRALDH1A1MAPTGAA
SCHEMBL3494115 0.84 POLB (0.47) TDP1POLBTSHRBCAT2ALDH1A1
SCHEMBL3491840 0.79 ALDH1A1 (0.62) TDP1POLBTSHRBCAT2ALDH1A1
SCHEMBL13341339 0.78 ALDH1A1 (0.75) TDP1POLBALDH1A1MAPTGAA
SCHEMBL3492121 0.76 ADORA3 (0.55) TDP1POLBTSHRBCAT2ALDH1A1
SCHEMBL3494356 0.76 TSHR (0.57) TDP1POLBTSHRBCAT2ALDH1A1
SCHEMBL3493372 0.76 POLB (0.53) TDP1POLBTSHRBCAT2ALDH1A1
SCHEMBL3494830 0.75 ALDH1A1 (0.52) TDP1POLBTSHRBCAT2ALDH1A1
SCHEMBL3492382 0.75 KMT2A (0.59) TDP1POLBTSHRALDH1A1MAPT
SCHEMBL3494438 0.75 POLB (0.52) TDP1POLBTSHRBCAT2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10870656-B2 Methods for treatment of heart failure CARDURION PHARMACEUTICALS, LLC (US) 2020-12-22 US disclosed
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE CARDURION PHARMACEUTICALS LLC (US) 2019-07-11 US disclosed
EP-1908765-B1 THIENOPYRIMIDINE DERIVATIVE ASKA PHARM CO LTD (JP) 2014-10-22 EP disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377944-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES GOTANDA KOTARO (JP) 2013-01-24 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8293754-B2 Thienopyrimidine derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
US-20090203703-A1 Thienopyrimidine Derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-08-13 US disclosed
EP-1908765-A1 THIENOPYRIMIDINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD TDP1 409/4885POLB 555/4885TSHR 4386/4885
US-10870656-B2 Methods for treatment of heart failure TNNT2, TNNI3, TNNC1 TDP1 1594/4885POLB 1353/4885TSHR 1988/4885
US-20130023546-A1 THIENOPYRIMIDINE DERIVATIVES PDE9A, BPHL, THOP1 TDP1 76/4885POLB 2134/4885TSHR 879/4885
US-20090203703-A1 Thienopyrimidine Derivatives PDE9A, BPHL, THOP1 TDP1 76/4885POLB 2134/4885TSHR 879/4885
US-20190211028-A1 METHODS FOR TREATMENT OF HEART FAILURE TNNT2, TNNI3, TNNC1 TDP1 1594/4885POLB 1353/4885TSHR 1988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.